Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations

COSCIENS Biopharma

12/05/2026 22:14

Overview

Canada plant-based ingredient maker's Q1 revenue rose yr/yr on higher sales volumes

Q1 net income turned positive, driven by income from discontinued German operations

Operating expenses for Q1 halved from prior year due to cost reductions

Outlook

Company did not provide specific financial guidance for the current or future periods

Result Drivers

DISCONTINUED OPERATIONS - Net income was primarily driven by $10.9 mln income from discontinued German subsidiaries after their deconsolidation

COST REDUCTIONS - Operating expenses fell due to lower selling, general and administrative costs and reduced R&D spending

HIGHER SALES VOLUMES - Revenue increased yr/yr due to higher sales volumes

Company press release: ID:nGNX6XYjwC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
$10.80 mln
Q1 Operating Expenses
$1.50 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)